Charlie Schmidt. Show Affiliations »
Abstract
Mesh： See more » Antineoplastic Agents/therapeutic useClinical Trials as Topic/trendsCrizotinibDiagnostic Test Approval/standardsDiagnostic Test Approval/trendsDrug ApprovalDrug LabelingHumansIndoles/therapeutic useMelanoma/drug therapyMolecular Targeted Therapy/trendsMutationNeoplasms/diagnosisNeoplasms/drug therapyNeoplasms/geneticsPatient SelectionPrecision Medicine/trendsPyrazoles/therapeutic usePyridines/therapeutic useSulfonamides/therapeutic useUnited StatesUnited States Food and Drug AdministrationVemurafenib
Substances： See more » Antineoplastic AgentsIndolesPyrazolesPyridinesSulfonamidesVemurafenibCrizotinib
Year: 2011 PMID： 22173588 DOI： 10.1093/jnci/djr535
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506